Abstract
Real-world data (RWD) from electronic health records (EHRs) and administrative claims databases are used increasingly to generate real-world evidence (RWE). RWE is used to support clinical evidence packages for medicines that inform decision-makers. In this review of current issues in the use of RWD-derived external comparator groups to support regulatory filings, we assess a series of topics that generally apply across many disease indications. However, most of the examples and illustrations focus on the oncology clinical research setting. The topics include an overview of current uses of RWD in drug development, a discussion of regulatory filings using RWD-derived external comparators, a brief overview of guidance documents and white papers pertaining to external comparators, a summary of some limitations and methodological issues in the use of external comparator groups and finally, a look at the future of this area and recommendations.

Keywords
External comparators · External controls · Historical controls

Background
Real-world data (RWD) from electronic health records (EHRs) and administrative claims databases are used increasingly to generate real-world evidence (RWE). RWE is used to support clinical evidence packages for medicines that inform decision-makers. For instance, there is growing attention to the use of externally derived patient data to augment control groups in randomized clinical trials and as a proxy control group in single-arm clinical trials, particularly in clinical oncology where single-arm trials are common [1–18]. Much of the interest in patient data derived to contextualize clinical trials stems from recent changes in the United States regulatory landscape [7, 9, 11, 13, 19–30]. These changes include interpreting single-arm trial results for new drug applications, extending benefit-risk assessments to broader populations beyond those participating in clinical trials to patients found in RWD cohorts, and product label extensions [18, 20, 29, 31–35]. The regulatory shift is evinced through legislation such as the 21<sup>st</sup> Century Cures Act in 2016, the evolving Prescription Drug Users Fee Act (PDUFA), the 2018 US Food and Drug Administration (FDA) guidance on the use of RWE in regulatory
decision making (FDA Framework for RWE),\textsuperscript{1} and research initiatives such as the 2017 National Cancer Institute Cancer Moonshot [31–33, 36, 37]. The changing regulatory landscape is not unique to the USA, as health authorities in other jurisdictions, such as the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan, and Health Canada, have all issued recent statements regarding the developing role of RWD in drug development [38–40].

Changes in regulatory practice are not the only reason for the increased focus on externally derived control groups. The field of medicine has benefited from the advent and availability of next generation gene sequencing (NGS) platforms that have greatly enhanced oncology drug discovery and led to increased targeting of onco-genic mutations [41]. Many targeted oncology molecules are now following accelerated pathways such as FDA’s Breakthrough Therapy Designation, with a commensurate acceleration in the drug development cycle that can advance experimental therapies from phase 1B directly into phase III trials. For example, sortorabib was recently granted accelerated approval for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) [42]. In addition to speeding the drug development cycle, externally derived control groups can support situations in which randomization may not be possible or ethical, including when effective treatments are not available (e.g., novel biomarker targets) or current treatment options are suboptimal. There are numerous examples in oncology drug development where the unmet medical need is so pronounced that palliative care would be the only alternative to an experimental treatment. In yet other cases, the populations have rare biomarkers that make patient enrollment challenging. Collectively, these factors have resulted in a growing number of early phase single-arm oncology trials and increasing attention to “hybrid” designs in later phase trials, which include randomized controls augmented with external controls.

The availability, completeness, and quality of RWD, especially EHR databases, has been steadily improving. These EHR databases can augment structured data fields with unstructured information gleaned from text fields in the medical charts. Also, the data are more contemporaneous, with very little lag between the time of a medical encounter and the data becoming available for analysis. There is also better characterization of important biomarkers as testing practices increase over time. Linkage of data sources such as EHRs with administrative claims databases provides additional granularity and completeness and fills in important missing gaps in the patients’ clinical, treatment and demographic profiles. Finally, the overall quality of important endpoint and clinical outcomes like mortality and disease response has been critically assessed and validated in some EHRs [43–45].

The use of RWD for externally derived comparator groups raises important methodologic considerations. To address selection bias and other forms of study bias, statistical methods to control for bias and confounding have continued to evolve [46–53]. Developing methods include the use of target trial emulation principles to avoid various forms of bias, including selection bias, the use of summary confounder scores such as a propensity score (PS) and methods for assessing and controlling unmeasured confounding, as accomplished with negative controls and use of instrumental variables [46–51].

In this review of current issues in the use of RWD-derived external comparator groups to support regulatory filings, we assess a series of topics that generally apply across many disease indications. However, most of the examples and illustrations will focus specifically on the oncology clinical research setting. The topics included in the review are as follows:

- An overview of current uses of RWD in drug development
- Regulatory filings using RWD-derived external comparators
- Guidance documents and white papers pertaining to external comparators
- Limitations and methodological issues in the use of external comparator groups
- A look at the future of this area and recommendations

### Overview of Uses of RWD-derived External Comparators

Historical controls generally refer to the use of patient cohorts derived from previously conducted clinical trials that are repurposed for use in the assessment of treatment effects or adverse events observed in other clinical trials. In addition to concerns about limited availability of critical variables, the use of historical control arms as comparators for single-arm trials have been criticized because the historical data may not reflect current standard of care. The increasing availability of more contemporary RWD enables concurrent comparisons, and accordingly, the nomenclature for these types of applications has evolved from historical controls to external, synthetic, or virtual controls/comparators [3, 6, 10, 54, 55].

Several uses exist for combining externally derived cohorts with clinical trial data. The corresponding point

\textsuperscript{1} An update to the FDA’s Guidance on the use of RWE to support regulator decision making is expected in the coming months, with a draft version released on September 29, 2021.
in a medicine’s development lifecycle where an application is relevant is depicted in Fig. 1. These main applications are elaborated on in Table 1 and are discussed below.

**Table 1** Description of use cases using external control groups/comparators across the drug development lifecycle

| Approach                        | Purpose                                                                 | Development phase                   |
|---------------------------------|------------------------------------------------------------------------|-------------------------------------|
| 1. Disease natural history     | Provide descriptive baseline clinical and demographic information describing unmet medical need and natural history of disease | Early phase trials                  |
| 2. Single-arm trial direct comparisons | Evaluate and interpret treatment effect in single-arm trials with direct comparisons with comparator data | Early phase trials                  |
| 3. Hybrid trials               | Expose fewer patients to suboptimal standard of care while maintaining a component of randomization. Accelerate trial enrollment and reduce study time by including external comparators in the non-interventional arm and increase number of patients in the experimental arm to increase safety database | Late phase randomized trials        |
| 4. Indirect treatment comparisons | Assessment of treatments not included in trial standard of care      | Early and late phase trials and post-marketing safety studies |
| 5. Post-marketing comparative safety studies | Interpret safety events in single exposed cohorts/registries | Post-marketing                      |

**Assessing Treatment Effects in Early Phase Single-Arm Trials: Direct Comparisons Using External Comparator Arms**

When appropriate RWD are available they can be used to make direct comparisons to trial experimental arms. RWD-derived external comparators can mimic the overall health, demographic, and disease characteristics of the trial arm through application of a trial’s inclusion and exclusion criteria (Fig. 2A). However, these non-randomized comparisons are subject to potential biases. For example, the prevalence of a biomarker that defines the trial population could differ in the RWD control group, introducing selection bias and threatening comparability. To reduce selection bias, the RWD-derived controls should be sampled from a similar underlying population as the treatment arm. To compensate for potential bias and confounding between the trial arm and the externally derived comparator arm, appropriate adjustment methods (e.g.,
propensity score matching and weighting) and sensitivity analyses should be incorporated into the analyses [6, 8].

Despite growing interest and potential, relatively few studies have used external controls as a means of interpreting data from clinical trials. One of the first examples is a study by Gökbuget et al. comparing outcomes from a single-arm trial in relapsed/refractory acute lymphoblastic leukemia patients to an external comparator [57]. These researchers constructed an external control group using RWD to compare response and survival between the external comparator and clinical trial. The data were included in regulatory filings and played an important role in the FDA’s accelerated approval of blinatumomab [58]. The efficacy of blinatumomab versus standard of care chemotherapy was further confirmed in a phase 3 randomized controlled trial two years later [59]. The concordance of the findings provided additional support for the use of external controls.

Tan and colleagues took a different approach than the blinatumomab example by extracting data from published single-arm trials in patients treated with crizotinib for
anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (mNSCLC) [60] and comparing the aggregate findings with single-arm studies in NSCLC patients treated with ceritinib. The comparison demonstrated an advantage for crizotinib in progression-free survival (PFS) and overall survival (OS) [60]. Other research using external controls have also shown early promise [12, 54, 55], including studies drawing on aggregate findings from the clinical trial literature in acute myeloid leukemia and anaplastic lymphoma kinase-targeted NSCLC; each of these efforts demonstrated the promise of external controls for interpreting findings from single-arm trials [54, 60, 61].

A recent study drew on data from 11 advanced NSCLC (aNSCLC) randomized trials and substituted data from an oncology EHR database [8] for the controls arms from the clinical trials. In most cases, the researchers were able to replicate closely the hazard ratios for overall survival from the original randomized trials [8].

**Accelerating Late Phase Trials: Hybrid Designs Using External Controls**

Innovative study designs for late phase oncology trials are another opportunity for using external controls. In the past, the purpose of so-called adaptive trials was to channel more patients to the RCT experimental arm that was experiencing better outcomes [35]. Hybrid trials have a couple of different meanings by regulators [35]. There are hybrid trial designs that use EHR data to collect information on patients enrolled in trials and thereby reduce costs and timelines (see Zhu et al. 2020 for a comprehensive treatment of this design [62]). Another form of hybrid trial design, which shares similar objectives to both adaptive designs and the previously mentioned hybrid trials, are trials that augment randomized controls with controls from other trials or from RWD that share similar characteristics as those in the trial [1, 26, 62]. These hybrid designs expose a smaller proportion of randomized subjects in the clinical trial to a potentially suboptimal standard of care, and the external data (historical clinical trial and/or RWD) are used to supplement the randomized control. In some cases, Bayesian approaches are used to assess commensurability between the external controls and the trial patients over time [1, 4, 62]. The assessment of the commensurability between the trial data and the external cohort takes place incrementally over the course of the trial enrollment period and may involve techniques that select controls from the external data based on the assessment of commensurability with respect to the trial outcome (e.g., the greater the commensurability, the more external patients selected to augment the trial patients). Figure 2B shows a simplified version of the hybrid trial design using a post hoc “all or none” selection of external controls approach in a fictional trial where a 3:1 randomization scheme is used. The purpose of these approaches is to accelerate trial enrollment, expose fewer patients to suboptimal treatments, and ultimately bring innovative potentially lifesaving or life-extending medicines to patients sooner.

**Indirect Comparative Effectiveness**

Indirect treatment comparison in the pre-approval and post-marketing settings allow for comparisons between experimental treatments or newly marketed drugs respectively, with novel or new standard of care marketed treatments. Using external RWD cohorts standardized to trial eligibility criteria, treatment effects are characterized between a trial experimental treatment and some standard of care treatment in the RWD [60, 61]. The RWD cohort is then re-standardized to a published trial that compares the same standard of care with another newer novel marketed therapy [63]. Additional adjustment can be achieved through weighting on aggregate level baseline characteristics [63]. The analysis involving the published trial data can be accomplished using software that converts digital Kaplan–Meier (KM) curves using a pixel-based conversion approach that reconstructs the published KM curve with the RWD external comparator in the same KM plot [63, 64]. The same technique may be used to extract a novel treatment from the published literature and plot a KM graph comparing the novel treatment with an experimental treatment from a trial.

**Post-marketing Safety Studies and Long-term Safety Follow-up**

Post-marketing safety studies containing a single exposed cohort is another setting where the use of externally derived cohorts can aid in the interpretation of study findings [19]. For example, in prospective studies examining rare populations where an internal comparator is infeasible due to enrollment challenges (e.g., idiopathic pulmonary fibrosis), an external comparator arm derived from a large administrative claims database can be beneficial for evaluating important safety endpoints. Often pregnancy safety exposure registries will capture data only on exposed patients, making interpretation of potential safety signals challenging in the absence of an unexposed control group. These studies may rely on the published data to interpret safety signals, which may be outdated and may not reflect the same patient characteristics found in the registry. Finally, long-term safety studies could be conducted using data from RWD-derived patient cohort as an extension to the trial observation period allowing for adequate follow-up of important safety endpoints [6].
Regulatory Filings Using RWD-derived External Comparators

Regulatory reviews of hematology and oncology new drug applications (NDAs) and labeling extensions submitted by drug developers using data from single-arm trials is increasing [7, 16, 24, 65–67] (Fig. 3). Despite the growth in single-arm study approvals, RWD have been included in very few evidence packages. This trend could change in response to the December 2016 enactment of the 21st Century Cures Act and the subsequent initiation of the NCIs Cancer Moonshot program in 2017. Bolislis et al. (2020) reviewed NDAs and labeling extensions using RWD submitted to the EMA, FDA, PMDA, and Health Canada over the past 20 years and found only 27 cases where RWD was used, primarily in the oncology disease area [16]. In addition to the blinatumomab example mentioned above, there are five other examples of favorable FDA decisions that considered RWD. These include label expansions for blinatumomab, avelumab approval for metastatic Merkel cell carcinoma, and axicabtagene ciloleucel approval for relapsed or refractory large B-cell lymphoma [16, 68]. Although not an example of an RWD external comparator analysis, palbociclib received an approval in metastatic male breast cancer based in part on evidence from RWD [69].

There are also examples where drug developers have been unsuccessful using RWD-derived control arms as part of their FDA filing. Despite receiving Breakthrough Therapy Designation for relapsed or refractory multiple myeloma (RRMM), in the selinexor submission, the regulators commented on study design issues, differences in the EHR population compared to the trial patients, and methodologic issues, which led them to conclude that the RWD “is not adequate to provide context or comparison for the overall survival observed” in the clinical trial patients [70]. Additionally, the regulators expressed concerns about the RWD study not being pre-specified, as the study protocol was not submitted a priori to the FDA [70]. In 2019, the sponsor of tazemetostat, indicated in epithelioid sarcoma patients, had their RWD evidence disregarded by the FDA due to lack of pre-specification of the study protocol and concerns about the study design and methods [71]. Again in 2019, the FDA did not consider the submitted RWD-derived control arms for the filings for both erdafitinib, a fibroblast growth factor receptor positive (FGFR+) targeted therapy for patients with advanced or metastatic urothelial cancer, and entrectinib, for ROS1+ metastatic non-small cell lung cancer. The FDA cited concerns related more to the generalizability of the EHR cohorts than to concerns related directly to their methodologies [72, 73].

In 2020, an external comparator study was submitted to the FDA (RE-MIND: NCT04150328) to support the NDA for tafasitamab indicated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [74]. This analysis aimed to provide context for interpreting the efficacy findings observed in the single-arm L-MIND pivotal trial for patients with DLBCL. The primary objective of the study was to isolate the contribution of tafasitamab to efficacy of a tafasitamab...
plus lenalidomide regimen in a cohort of RWD patients matched to trial patients from L-MIND. Data for the L-MIND patients were collected from clinical trials and data for the RE-MIND patients were collected from the medical records of patients in real-world settings. Of note, there were different study periods for the trial patients (2016 to 2018) and the RWD patients (2007 to 2019) [74]. In the FDA decision, the reviewers noted the following concerns:

The validity of the study is compromised by several limitations in the study design. Bias resulting from key differences in patient selection and unequal distribution of important measured and unmeasured prognostic indicators between treatment arms are likely to favor survival for the L-MIND patients. Most importantly, given important differences in the patient populations included in the L-MIND trial and RE-MIND study, primarily as a result of selection bias, this study does not provide sufficient evidence to isolate the contribution of tafasitamab to efficacy of tafasitamab+LEN combination therapy for DLBCL” (Page 3) [74]

This survey of reviews conducted by the FDA indicates that regarding the use of RWD-derived external comparators for contextualizing single-arm trials, these are at best early days in terms of acceptance. Concerns relate to selection bias, generalizability of RWD, and the resulting inherent differences in baseline covariates between RWD comparators and trial patients, as well as the capture and completeness of important prognostic factors in RWD.

**Best Practices: Guidance Documents and White Papers**

Given the growing interest in external controls, there are several recent guidance documents, best practices, and white papers in circulation devoted to the subject. FDA’s *Framework for Real-World Evidence Program* discusses the role of external controls in the context of single-arm trials using either historical clinical trial data or RWD:

Collection of RWD on patients currently receiving other treatments, together with statistical methods, such as propensity scoring, could improve the quality of the external control data that are used when randomization may not be feasible or ethical, provided there is adequate detail to capture relevant covariates. (page 20) [33]

The *Framework* suggests limitations such as a lack of standardized diagnostic criteria and study endpoints, and general concern with the comparability of RWD patient populations with trial patients [33]. Other regulatory agencies, including EMA, PMDA, and Health Canada, have commented on the role of RWD in regulatory filings [38–40].

Many recent commentaries discuss the use of RWD-derived external controls and their use in drug development [5, 6, 9, 10, 15, 17, 19, 22]. Common recommendations for when to use RWD include single-arm trials where randomization is infeasible or unethical, label expansions, long-term follow-up, and augmenting randomized control groups in hybrid designs. An additional rationale relates to drugs that fill high unmet medical need where filings with single-arm studies receive accelerated approval (e.g., see sortorsib example above) and are followed by randomized phase 3 study as part of a post-marketing requirement.

**Methodological and Other Considerations**

This section highlights analytic issues (e.g., bias and confounding) that may arise when external RWD cohorts are combined with clinical trial data as well as some general considerations (see Table 2).

FDA and other regulators have repeatedly noted concern regarding how well RWD populations reflect clinical trial patients in terms of clinical and demographic characteristics and potentially unobserved prognostic factors. Although these differences can be controlled using statistical methods, this ability depends on data, especially prognostic factors, being available in the RWD. Additionally, differences in biomarker testing practices between RWD and trials can complicate studies specific to certain genetic mutations or protein expression. In the real-world setting patients may be tested late in the disease process, whereas patients enrolled in trials will be tested at the outset of the study. This difference in timing can affect trial results especially for those trials which are conducted in patients treated in the first line.

The use of concurrent controls from the RWD can help address changes to standard of care treatments that are common in oncology. Other issues in using RWD include endpoints like treatment response and disease progression that can differ in how they are defined and collected in clinical trials versus RWD [75]. Mortality, although well captured in some inpatient EHRs, is still less complete than found in clinical trials [43, 44] and missing death data could lead to underestimation of mortality in the control arms [44]. In addition, many EHR databases only include US patients, whereas trial populations are often global and disease prognosis can vary by region.

Trials conducted in later lines of treatment can complicate selection of an appropriate index date or “time 0” for RWD analyses. A biomarker test date may occur after the initiation of treatment, introducing an “immortal” period.
| Methodological issues and other considerations | Significance or study impact |
|-----------------------------------------------|-------------------------------|
| **Data issues**                               |                               |
| Internal validity and study generalizability  |                               |
| Predominantly community-based oncology care in the US-based EHR data | Issues with comparability of RWD and trial patients and potential impact on study internal validity |
| Are the RWD contemporaneous with trial period? | Changes in the standard of care can greatly affect analyses with outdated standard of care often causing bias in favor of the experimental treatment |
| US-based EHRs versus global trials            | Regional differences in prognosis related to treatments and differences in health care delivery may threaten the external validity of the study findings |
| Biomarker testing practices                   | There may be differences between RWD patients and trial patients with respect to specific mutations or protein expression in terms of when the testing took place. Trial patients are tested at the outset of the study whereas costly NGS testing may take place very late in the disease process in patients in the real-world setting, often as a last resort |
| **Information bias**                          |                               |
| Comparability of RWD endpoints                | Comparability of study endpoints: difference in important endpoints like disease progression between RWD and trials can introduce bias |
| Efforts should be made to validate endpoint like mortality against known gold standard to understand the potential for underestimation of mortality in the RWD patients |
| Data ascertainment                            | Differences in timing of data collection and data measurement: Differences in biomarker testing practices with testing often conducted in later lines in RWD versus early on in trials; ECOG not routinely collected in RWD; serial measurement of lab data not as likely in RWD |
| **Design and analysis issues**                |                               |
| Handling and assessment of missing data       | Missing mortality in the external comparator may result in an overestimate of survival in the external comparator group introducing a bias in favor of the standard of care group |
| Selection of comparator lines and time origin | Selection of comparator lines and time origins may introduce selection bias and immortal time periods. Care must be taken so the selection of comparators and the start of follow-up doesn't require knowledge of things that occur in the future |
| Bias analyses pre-specified                   | Pre-specifying probable study challenges will enhance study credibility (e.g., handling of missing data and data related limitations that require certain assumptions) |
| Study size challenges                         | Rare indications with biomarkers may cause challenges in gathering sufficiently large study sizes in RWD |
| **Confounding**                               |                               |
| Use of appropriate adjustment methods to control for confounding | Best practices are continuously evolving requiring researchers to stay current on advances in methodology and statistics |
| Direct statistical comparison versus informal comparisons | Debate as to the appropriateness of statistical comparisons between trials and external data |
| Use of methods to control for unmeasured confounders | Not all covariates captured in RCTs will be measured and recorded in RWD requiring use of methods such as negative controls or use of instrumental variables |
| Data linkage to capture missing covariates    | Complete view of patient health is sometimes missing in oncology specific EHR databases with need to link with other data sources |
| **Regulatory and other considerations**       |                               |
| Regulatory context                            | Does a strong rationale exist for the use of RWD in place of a randomized trial? E.g., would it be unethical to design a trial that includes randomization to a suboptimal treatment option? |
| Communication with regulators                 | A priori communication with drug regulators such as FDA and EMA is important to ensure a clear shared understanding of strengths and limitations of any RWD analysis. Clear communication with regulators is suggested with pre-submission of study protocols and analysis plans |
between the time of treatment initiation and the required test result (because if the patient died, the test would not be performed, so all patients with the test result had to be alive through the date of the test) [76, 77]. Figure 4A and B illustrates this point in studies examining first- and second-line-treated patients respectively.

There are multiple methods available to address possible shortcomings of RWD, including negative controls, instrumental variables, propensity scores (PS), and high-dimensional PS [13, 47, 48, 50, 51, 78]. Other methods such as inverse probability of censoring and time to censoring for handling potential informative censoring bias stemming from missing outcomes like mortality can improve the integrity of the analysis [52]. Quantitative bias analysis can be used to assess the robustness of findings and assumptions [53]. Approaches such as study restriction by line of treatment, stratification or statistical adjustment by line of treatment can also be used. An assessment of important confounders not captured in RWD may point to the need for additional data abstraction of these potential confounders. Many of these issues can be addressed through thoughtful study design and analysis.

Transparency about data limitations, comparability of treatment groups and other potential sources of bias is crucial. In oncology and other diseases areas with high mortality or morbidity, regulators must make benefit/risk determinations and a common understanding of what can, and cannot, be inferred from the RWD comparisons serves regulators and sponsors, but most of all patients.

### Table 2 (continued)

| Methodological issues and other considerations | Significance or study impact |
|-----------------------------------------------|-----------------------------|
| **Clinical context**                          | High unmet medical need can provide a strong rationale for single-arm trials that would get medicines to clinicians and patients faster |
| **Data knowledge and expertise**              | Detailed knowledge of data capture, quality, and workflows are needed for appropriate use of RWD for external comparators |

![Fig. 4 A Immortal time bias in initial treatment period. “Patient 1” in panel A has an immortal period following initiation of treatment and the test result. To handle this immortal time bias, patients can be excluded altogether or alternatively, patients’ time 0 can be changed from the start of treatment to the test date. B Illustration of an immortal period in second-line treatment (“Patient 3”). Also, it can be seen that “Patient 1” despite having a test date after the start of first-line treatment is still appropriately eligible for an analysis focusing only on second-line treatment.](image-url)
The Future of External Comparators

Changes in the regulatory landscape have led to an increased focus on the use of RWD as external comparators in the clinical evidence package used in regulatory drug submissions in oncology. To date, best practices are still being established and debated among the scientific community with many groups such as the FDA, Drug Information Association, Friends of Cancer Research, American Society for Clinical Oncology, and the International Society for Pharmacoepidemiology currently working on guidance around the use of external comparators as part of the clinical evidence package [6, 17, 25, 26, 30, 33, 78]. Adoption of these approaches will hinge on continued dialogue and scientific exchange with a view to producing credible evidence to support drug development efforts.

What does the future hold? Inevitably, there will be ever greater availability of RWD data sources in oncology with more granularity and improved quality, including growing capture of NGS and other biomarker test results. Methods to account for bias and confounding will continue to evolve. One of the major challenges will be to synthesize the empirical findings into a coherent model that captures the more salient learnings from a wide spectrum of researchers. Our ability to do this in a thoughtful and collaborative way across the various stakeholders will ultimately decide the role that RWD will play in drug development.

When viewed from the various stakeholder perspectives, whether patients, drug developers, regulatory agencies, or payers, there is a common shared interest in accelerating oncology drug development. For patients diagnosed with cancer, the prospect of novel treatments becoming available that may be able to help extend their life is obviously crucial. Biopharmaceutical companies have as their core mission the development of effective and safe treatments to combat life-threatening disease. Single-arm studies can accelerate the approval process in settings with a high unmet medical need and get medicines to patients faster. Using RWD-derived control arms to evaluate efficacy can also inform better decision making. Regulators also have as their mission to bring safe and effective medicines to patients in a timely fashion. Finally, payers would benefit from the availability of more suitable targeted treatments with enhanced prognoses that would in the long run justify the cost of newly developed treatments. With all the apparent advantages that RWE can potentially provide to the traditional drug development paradigm come myriad concerns related to poorly designed RWD/clinical trials or RWD that is used in settings where it is not appropriate or warranted. These lingering concerns makes it even more important to focus on advancing the scientific knowledge base pertaining to the use of RWD in clinical drug development.

Declarations

Competing Interests Drs. Carrigan, Bradbury, and Chia are employees of Amgen with stock holdings in Amgen. Drs. Capra and Taylor are employees Genentech with stock holdings in Genentech. Dr. Sarsour is an employee of Janssen with stock holdings in Janssen. Dr. Brown has no competing interests to declare. Dr. Rothman is an employee of the Research Triangle Institute, an independent nonprofit research organization that does work for government agencies and pharmaceutical companies. Dr. Brookhart has provided past epidemiology consulting services for Amgen.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Han B, Zhan J, Zhong ZJ, Liu D, Lindborg S. Covariate-adjusted borrowing of historical control data in randomized clinical trials. Pharm Stat. 2017;16:296–308.
2. Hiemenz JW, Raad II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis. 2010;29:1387–94.
3. Davi, R, Chandler M, Elashoff B, et al. Results of a randomized control arm are replicated by a synthetic control arm; a case study in NSCLC; ASCO, abstract #9108, 2019.
4. Yin PT, Desmond J, Day J. Sharing historical trial data to accelerate clinical development. Clin Pharmacol Ther. 2019;106:1177–9.
5. Gray CM, Grimson F, Layton D, Pocock S, Kim J. A framework for methodological choice and evidence assessment for studies using external comparators from real-world data. Drug Saf. 2020;43:623–33.
6. Steeger JD, Davis KJ, Iannacone MR, et al. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. Pharmacoepidemiol Drug Saf. 2020;29:1382–92. https://doi.org/10.1002/pds.5141.
7. Gorring S, Taylor A, Müller K, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2):e024895–e024895.
8. Carrigan G, Whipple S, Capra WB, et al. Using electronic health records to derive control arms for early phase single-arm lung cancer trials: proof-of-concept in randomized controlled trials. Clin Pharmacol Ther. 2020;107(2):369–77.
9. Burcu, M, Dreyer, NA, Franklin, JM, et al. Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms. Pharmacoepidemiol Drug Saf. 2020;1–8.
10. Mack C, Christian J, Brinkley E, Warren EJ, Hall M, Dreyer N. When context is hard to come by: external comparators and how to use them. Ther Innov Regul Sci. 2019. https://doi.org/10.1177/2168479019878672.
11. Jarow JP. Use of external controls in regulatory decision-making. Clin Pharmacol Ther. 2017;101:595–6.

12. Patel K, Owens M, Shire N, Khosla S. The application of electronic medical records (EMRs) as a virtual comparator arm in a lung cancer clinical trial: a case study. J Clin Oncol. 2017;35(suppl.15). Abstract e18098.

13. Abrahimi D, Pradhan R, Yin H, Honig P, Andre EB, Azoulay L. Use of real-world data to emulate a clinical trial and support regulatory decision-making: assessing the impact of temporality, comparator choice and methods of adjustment. Clin Pharmacol Ther. 2021 Feb;109(2):452–61. https://doi.org/10.1002/cpt.2012.

14. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13(1):41–54.

15. Thorlund K, Dron L, Park JJJ, Mills EJ. Synthetic and external controls in clinical trials - a primer for researchers. Clin Epide miol. 2020;12:457–467. Published 2020 May 8.

16. Bolislis WR, Fay M, Kübler TC. Use of real-world data for new drug applications and line extensions. Clin Ther. 2020;42(5):926–38.

17. Ghadessi et al. A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) Orphanet Journal of Rare Diseases. 2020;15:69. https://doi.org/10.1186/s13023-020-1332-x.

18. Khizin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109:djx187.

19. Franklin IM, Sneeewess S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102:924–33.

20. Sridhara R. External controls in cancer clinical trials – challenges and opportunities. US Food and Drug Administration. Presented at: Clinical Trials and Translational Research Advisory Committee. 2019. https://deainfo.ncti.nih.gov/advisory/ctac/0719/Att%203_External%20Controls%20in%20Cancer%20Clinical%20Tri als_Sridhara.pdf. Accessed 20 Dec 2020.

21. Schmidli H, Häring DA, Thomas M, et al. Beyond randomized clinical trials: use of external controls. Clin Pharmacol Ther. 2020;107(806–816):30.

22. Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Ther Innov Regul Sci. 2018;52:362–8.

23. Hatswell AJ, et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open. 2016;6:e011666.

24. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoeconomics Drug Saf. 2019;1:12.

25. Friends of Cancer Research. Exploring whether a synthetic control arm can be derived from historical clinical trials that match baseline characteristics and overall survival outcome of a randomized control arm: case study in non-small cell lung cancer. 2018. https://www.focr.org/sites/default/files/pdf/SCA%20White%20Paper.pdf. Accessed 18 Dec 2020.

26. Friends of Cancer Research. Characterizing the use of external controls for augmenting randomized control arms and confirming benefit. 2019. https://friendsofcancerresearch.org/wpcontent/uploads/2019/06/Panel_1_Slide_Desk_AM19.pdf. Accessed 18 Dec 2020.

27. Jarow JP, LaVange L, Woodcock J. Multidimensional evidence generation and FDA regulatory decision making defining and using “real-world” data. JAMA. 2017;318:703–4.

28. Khizin S, Kim G, Pazdur R. From big data to smart data: FDA’s INFORMED initiative. Nat Rev Drug Discov. 2017;16:306.

29. Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867–8.

30. Mahendraatrnam N, Eckert J, Mercon K, et al. Using secondary data to generate real-world evidence for regulatory decision making, and demonstrating their credibility. Duke-Margolis Center for Health Policy. 2019. https://www.healthpolicy.duke.edu/sites/default/files/2020-08/Non-Interventional%20Study%20Credibili ty.pdf. Accessed 20 Dec 2020.

31. United States Congress. 21st Century Cures Act. https://www.congress.gov/bill/114th-congress/house-bill/34/ (2016).

32. Cancer Moonshot. https://www.cancer.gov/research/key-initi atives/moonshot-cancerinitiative. Accessed June 10, 2018.

33. US Food and Drug Administration. Guidance for FDA’s RWE Program. 2018. https://www.fda.gov/media/120060/download (Accessed Aug 02, 2020).

34. US Food and Drug Administration. Guidance for industry: rare diseases: natural history studies for drug development. US Department of Health & Human Services; March 2019.

35. US Food and Drug Administration. Guidance for industry: adaptive designs for clinical trials of drugs and biologics. US Department of Health & Human Services. 2019:33

36. US Food and Drug Administration: PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022. https://www.fda.gov/media/99140/download. Accessed 18 Dec 2020.

37. US Congress: Prescription Drug User Fee Act. P.L. 102–571,1992.

38. European Medicines Agency: EMA Regulatory Science to 2025 EMA/110706/2020

39. Utilizing Real World Data: A PMDA Perspective. https://globa lforum.diaglobal.org/issue/august-2018/using-real-world-data-a-pmda-perspective/ accessed 12/20/2020

40. Health Canada. Optimizing the use of real world evidence to inform regulatory decision making, health products and food branch notice April 16, 2019 Available at: https://www.canada.ca/en/health-canada/services/drugs-healthproducts/drugproducts/announcements/optimizing-real-world-evidenceregulatory-decisions.html

41. Wetterstrand KA. DNA Sequencing Costs: data from the NHGRI Genome Sequencing Program (GSP) (Available at: www.genome.gov/sequencingcostsdata. Accessed 12/18/2020

42. US Food and Drug Administration: FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC: https:// www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc accessed 7/2/2021

43. Curtis MD, Griffith SD, Tucker M, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res. 2018;53:4460–76.

44. Carrigan G, Whipple S, Taylor MD, et al. An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database. Pharmacoeconomics Drug Saf. 2019;28:572–81.

45. Griffith SD, Miksd RA, Calkins G, et al. Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set. JCO Clinical Cancer Informatics. 2019;1:13

46. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6:604–611. https://doi.org/10.1161/CIRCOUTCOMES.113.000359

47. Vanderweele TJ, Arah OA. Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. Epidemiology. 2011;22(1):42–52. https://doi.org/10.1097/EDE.0b013e318174493.
65. US Food and Drug Administration: New Drug Therapy Approvals 2018: https://www.fda.gov/drugs/new-drugs-fda-cdern-molec-ular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2018 (accessed November 17, 2020)
66. US Food and Drug Administration: New Drug Therapy Approvals 2019: https://www.fda.gov/drugs/new-drugs-fda-cdern-molec-ular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 (accessed November 17, 2020)
67. US Food and Drug Administration. BLA multidisciplinary review and evaluation: BLA 761049.Bavencio(Avelumab). https://www. accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000 MultidisciplineR.pdf. Accessed 02 Aug 2020.
68. US Food and Drug Administration. Ibrance Revisited Labeling; 2019 [FDA website]. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/nda/2019/207103Orig1s008. Accessed 02 Aug 2020.
69. Oncologic Drugs Advisory Committee Meeting, 2019 https:// www.fda.gov/media/121670/download (Accessed Aug 02, 2020). (Selinexor)
70. Oncologic Drugs Advisory Committee Meeting December 18, 2019 NDA 211723 Tazemetostat Applicant: Epizyme. Available at: https://www.fda.gov/media/133573/download. Accessed 02 Aug 2020.
71. US Food and Drug Administration. Memo: review of the sponsor’s white paper on comparison of overall survival between Erdafitinib clinical study BLC2001 patients and real-world control patients from observational data: https://www.accessdata.fda.gov/drugs atfda_docs/nda/2019/212018Orig1s000OtherR.pdf. Accessed 02 July 2020.
72. US Food and Drug Administration. Comparative analysis of ROS1-positive locally advanced or metastatic non-small cell lung cancer between patients treated in entrectinib trials and crizotinib treated patients from real world data. https://www.accessdata.fda. gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Or ig1s000OtherR.pdf. Accessed 02 July 2020.
73. An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203: Epidemiology: Review of Tafas tamab, RWE study report, May 5, 2020, https://www.accessdata. fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000OtherR.pdf. Accessed 02 July 2020.
74. US Food and Drug Administration: New Drug Therapy Approvals 2017: https://www.fda.gov/drugs/new-drugs-fda-cdern-molec-ular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2017 (accessed November 17, 2020)